Travere Therapeutics, Inc.
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients witā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$28.98
Price+6.39%
$1.74
1Y
Price
Market Cap
$2.673b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+26.8%
EBITDA Margin+15.6%
Net Profit Margin+8.6%
Free Cash Flow Margin+26.8%
EBITDA Margin+15.6%
Net Profit Margin+8.6%
Free Cash Flow MarginRevenue
$490.728m
+86.9%
1y CAGR+60.0%
3y CAGR+40.8%
5y CAGREarnings
-$50.261m
+72.5%
1y CAGR-18.7%
3y CAGR-27.7%
5y CAGREPS
-$0.56
+74.0%
1y CAGR-10.8%
3y CAGR-19.4%
5y CAGRBook Value
$114.828m
$605.191m
Assets$490.363m
Liabilities$328.733m
DebtDebt to Assets
54.3%
-14.6x
Debt to EBITDAFree Cash Flow
$37.784m
+76.3%
1y CAGR+7.0%
3y CAGR-107.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company